sST2 biomarker
Showing 1 - 25 of >10,000
Acute/Chronic Coronary Syndrome After Revascularization
Recruiting
- Myocardial Ischemia
- +2 more
- percutanous coronary angiography with stenting
-
Qinā, Egypt
- +1 more
Jan 6, 2023
Heart Failure Trial in Montpellier (Biomarker guided therapy)
Recruiting
- Heart Failure
- Biomarker guided therapy
-
Montpellier, Occitanie, France
- +1 more
Dec 31, 2021
sST2 and Troponin I-hs in Patients With Acute Chest Pain
Active, not recruiting
- Acute Chest Pain
- Acute Coronary Syndrome
- Multimarker approach in acute coronary syndrome
-
Roma, ItalySilvia Baroni
Feb 21, 2023
SGLT2 Inhibition in Heart Failure
Recruiting
- Heart Failure
- Sodium-glucose cotransporter 2 inhibitor
-
Belfast, United KingdomBelfast Health and Social Care Trust
Nov 15, 2023
Patients Hospitalized for Acute Heart Failure According to
Completed
- Heart Failure
- Evaluation of the evolution of biological markers from the biobank.
-
Nîmes, Gard, France
- +1 more
Jul 26, 2022
Mild Cognitive Impairment, Obstructive Sleep Apnea Trial in Hong Kong (Trazodone, Placebo)
Recruiting
- Mild Cognitive Impairment
- Obstructive Sleep Apnea
- Trazodone
- Placebo
-
Hong Kong, Hong KongThe Chinese University of Hong Kong
Jul 18, 2022
Gingival Crevicular Fluid in Periodontitis Type 2 Diabetes
Completed
- Periodontitis
- Diabetes Mellitus
-
Alexandria, EgyptFaculty of Dentistry, Alexandria University
Dec 19, 2022
Metastatic Breast Cancer, Unresectable Breast Cancer Trial in Saint Louis (DiviTum® TKa assay, CDK4/6 + Endocrine therapy)
Not yet recruiting
- Metastatic Breast Cancer
- Unresectable Breast Cancer
- DiviTum® TKa assay
- CDK4/6 + Endocrine therapy
-
Saint Louis, MissouriWashington University School of Medicine
Jul 27, 2023
Triple Negative Breast Cancer, HER2-positive Breast Cancer Trial in Seoul (exosome and ctDNA evaluation)
Active, not recruiting
- Triple Negative Breast Cancer
- HER2-positive Breast Cancer
- exosome and ctDNA evaluation
-
Seoul, Korea, Republic ofJi-Yeon Kim
Jul 13, 2023
Hepatocellular Carcinoma Trial (Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle)
Not yet recruiting
- Hepatocellular Carcinoma
- Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
- (no location specified)
Jun 12, 2023
ALS Trial ([11C]CPPC PET ligand)
Not yet recruiting
- ALS
- [11C]CPPC PET ligand
- (no location specified)
Jan 9, 2023
Sensitivity to Doxorubicin/Doxil in Soft Tissue Sarcoma
Active, not recruiting
- Soft Tissue Sarcoma
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Jan 25, 2023
Dementia Trial in Swansea (Venous blood collection)
Recruiting
- Dementia
- Venous blood collection
-
Swansea, United KingdomSwansea University
Sep 8, 2022
Multiparametric MRI asNon-Invasive Biomarker of Tumor
Recruiting
- Breast Cancer
- Triple-negative Breast Cancer
- Tempus assay
- +2 more
-
Nashville, TennesseeVanderbilt University Medical Center
Jan 10, 2023
Biomarkers Trial in Davis (Aim 1 Meal Challenge 1, Aim 1 Meal Challenge 2, Aim 1 Meal Challenge 3)
Recruiting
- Biomarkers
- Aim 1 Meal Challenge 1
- +5 more
-
Davis, CaliforniaUSDA ARS Western Human Nutrition Research Center
Jan 13, 2023
Sarcoma Trial in Shanghai (Apatinib monotherapy)
Recruiting
- Sarcoma
- Apatinib monotherapy
-
Shanghai, Shanghai, ChinaRuijin Hospital Shanghai Jiao Tong University School of Medicine
May 18, 2022
Intracerebral Hemorrhage Trial in Baltimore (MW189, Saline)
Not yet recruiting
- Intracerebral Hemorrhage
- MW189
- Saline
-
Baltimore, MarylandJohns Hopkins Hospital
Jul 5, 2022
Type1diabetes, Type 2 Diabetes, Adiposity Trial in Graz (No intervention)
Recruiting
- Type1diabetes
- +2 more
- No intervention
-
Graz, AustriaMedical University of Graz
Apr 5, 2022
Implementation ofNovel Functional Eye-Tracking Biomarker for
Recruiting
- Clinically Isolated Syndrome
- Relapsing Remitting Multiple Sclerosis
- Eye-tracking
-
Montréal, Quebec, CanadaMontreal Neurological Institute and Hospital
Sep 2, 2022
Glioblastoma Multiforme Trial in Calgary, Edmonton (Biomarker based treatment (Temozolomide monotherapy or Radiotherapy
Recruiting
- Glioblastoma Multiforme
- Biomarker based treatment (Temozolomide monotherapy or Radiotherapy monotherapy)
- Chemo-Radiotherapy consisting of 40 Gy in 15 daily fractions with concurrent temozolomide.
-
Calgary, Alberta, Canada
- +1 more
Jun 24, 2022
OCD, Post Traumatic Stress Disorder, Generalized Anxiety Disorder Trial in Boston, Austin (Exposure-Based Therapy)
Not yet recruiting
- Obsessive-Compulsive Disorder
- +4 more
- Exposure-Based Therapy
-
Boston, Massachusetts
- +1 more
Aug 9, 2022
Blood Self-Collection for Clinical Diagnostic Assessments Trial in Atlantis (Traditional Venipuncture, Tasso+)
Not yet recruiting
- Blood Self-Collection for Clinical Diagnostic Assessments
- Traditional Venipuncture
- Tasso+
-
Atlantis, FloridaAmerican Research Labs
May 1, 2023
Brain Concussion Trial (Neurolytixs Index)
Not yet recruiting
- Brain Concussion
- Neurolytixs Index
- (no location specified)
Mar 9, 2022
Periodontal Diseases Trial in Izmir (saliva obtaining)
Active, not recruiting
- Periodontal Diseases
- saliva obtaining
-
İzmir, Çiğli, TurkeyIzmir Katip Çelebi University Department of Periodontology
Mar 21, 2023